Literature DB >> 19427110

Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues.

Richard J Sylvester.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19427110     DOI： 10.1016/j.eururo.2009.04.043

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  4 in total

1.  Bladder cancer: meta-analysis of BCG versus mitomycin C--a deeper insight?

Authors:  Andreas Böhle
Journal:  Nat Rev Urol       Date:  2010-01       Impact factor: 14.432

2.  Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.

Authors:  Richard J Sylvester; Maurizio A Brausi; Wim J Kirkels; Wolfgang Hoeltl; Fernando Calais Da Silva; Philip H Powell; Stephen Prescott; Ziya Kirkali; Cees van de Beek; Thierry Gorlia; Theo M de Reijke
Journal:  Eur Urol       Date:  2009-12-18       Impact factor: 20.096

3.  Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.

Authors:  Stefanie Schmidt; Frank Kunath; Bernadette Coles; Desiree Louise Draeger; Laura-Maria Krabbe; Rick Dersch; Samuel Kilian; Katrin Jensen; Philipp Dahm; Joerg J Meerpohl
Journal:  Cochrane Database Syst Rev       Date:  2020-01-08

4.  Lycium barbarum polysaccharides inhibit proliferation and migration of bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway.

Authors:  Xian-Jun Zhang; Hong-Yuan Yu; Yong-Jian Cai; Mang Ke
Journal:  Oncotarget       Date:  2017-01-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.